LDL-Cholesterol: From the Hypothesis to Causality

被引：6
|
作者：
Custodis, Florian [1 ]
Laufs, Ulrich [1 ]
机构：
[1] Univ Klinikum Saarlandes, Abt Innere Med Kardiol Angiol & Internist Intensi, Homburg, Germany
来源：
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2015年 / 140卷 / 10期
关键词：
LDL; Cholesterol; LDL-Hypothesis; IMPROVE-IT; CORONARY-HEART-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; IMPROVE-IT; TRIALS; RISK; HYPERCHOLESTEROLEMIA; METAANALYSIS; SIMVASTATIN; PREVENTION; REDUCTION;
D O I：
10.1055/s-0041-102254
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The term "LDL-Hypothesis is frequently used to describe the association between LDL cholesterol (LDL-C) and cardiovascular outcomes. In the light of recent results of randomized trials the question arises whether the term hypothesis is still adequate. Considering the causal importance of LDL for the pathogenesis of atherosclerosis, epidemiological evidence and the clear genetic association of LDL-C with cardiovascular risk as well as the large statin trials and the reduction of events by a non-statin intervention in the IMPROVE-IT study, the term hypothesis appears to be outdated and should be replaced by LDL-causality.
引用
收藏
页码：761 / U71
页数：5
相关论文
共 50 条
  • [41] The in vivo oxidized LDL to LDL-cholesterol ratio is correlated with lipid content of LDL
    Wang, JJ
    Zhuang, YY
    Liu, XZ
    Chen, DI
    ATHEROSCLEROSIS, 2000, 149 (01) : 217 - 218
  • [42] Adherence to Statins and LDL-Cholesterol Goal Attainment
    Chi, Margaret D.
    Vansomphone, Southida S.
    Liu, In-Lu Amy
    Cheetham, T. Craig
    Green, Kelley R.
    Scott, Ronald D.
    Reynolds, Kristi
    AMERICAN JOURNAL OF MANAGED CARE, 2014, 20 (04): : E105 - E112
  • [43] Paroxetine: increased LDL-cholesterol in healthy volunteers
    Reactions Weekly, 2004, 985 (1) : 5 - 5
  • [44] Phytostanol tablets reduce human LDL-cholesterol
    McPherson, TB
    Ostlund, RE
    Goldberg, AC
    Bateman, JH
    Schimmoeller, L
    Spilburg, CA
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2005, 57 (07) : 889 - 896
  • [45] Addressing dyslipidemic risk beyond LDL-cholesterol
    Tall, Alan R.
    Thomas, David G.
    Gonzalez-Cabodevilla, Ainara G.
    Goldberg, Ira J.
    JOURNAL OF CLINICAL INVESTIGATION, 2022, 132 (01):
  • [46] LDL-Cholesterol and Platelets: Insights into Their Interactions in Atherosclerosis
    Gasecka, Aleksandra
    Rogula, Sylwester
    Szarpak, Lukasz
    Filipiak, Krzysztof J.
    LIFE-BASEL, 2021, 11 (01): : 1 - 13
  • [47] Analytical performance of a direct assay for LDL-cholesterol
    Smets, EML
    Péquériaux, NCV
    Blaton, V
    Goldschmidt, HMJ
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2001, 39 (03) : 270 - 280
  • [48] PRAVASTATIN REDUCES CHOLESTEROL AND LDL-CHOLESTEROL FOLLOWING PANCREAS TRANSPLANTATION
    ALHALAWANI, M
    LARSEN, JL
    MILLER, S
    FRISBEE, K
    STRATTA, RJ
    CLINICAL RESEARCH, 1994, 42 (03): : A413 - A413
  • [49] LDL-cholesterol, HDL-cholesterol or triglycerides - which is the culprit?
    Taskinen, MR
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2003, 61 : S19 - S26
  • [50] Is intensive LDL-cholesterol lowering beneficial and safe?
    Cheung, Bernard M. Y.
    Lam, Karen S. L.
    LANCET, 2010, 376 (9753): : 1622 - 1624
12345